| |
|
|
|
| |
PET Imaging of Tumor Proliferation
Drug Discovery & Development- March 2010
The Director of Imaging from our Discovery and Imaging Services group had his article entitled “PET Imaging of Tumor Proliferation” published in the March 2010 issue of Drug Discovery & Development. Positron emission tomography (PET) technology strategies have been effectively used in oncology drug research in both the preclinical and clinical stages. The article highlights two PET tracers for oncology that are currently in development, [18F]-3′-deoxy-3′-L-fluorothymidine ([18F]-FLT) and [18F]-1-(29-deoxy-29-fluoro-b-D-arabinofuranosyl) thymine ([18F]-FMAU). The PET tracers discussed are injected intravenously in a patient or research animal and allow for a PET image to be interpreted as a three-dimensional map of cellular proliferation in specific tissues, such as a tumor. The three dimensional map generated with the help of the new tracer candidates discussed will further enhance the value of using PET technology as a tool in assessing efficacy in the preclinical and clinical stages of oncology drug development.
Click here to read the full article.
|
|
PET Imaging, Positron emission tomography, PET Tracers, imaging, Tumor Proliferation, Drug Discovery & Development, drug discovery, drug development, oncology research, preclinical, clinical [18F]-FLT, [18F]-FMAU, drug efficacy
PET Imaging of Tumor Proliferation | Drug Discovery & Development
PET imaging produces 3-D images of positron-emitting radioisotope distribution after an intravenous injection of a radioisotope-labeled tracer. This article highlights two PET tracers for oncology currently in development, [18F]-FLT and [18F]-FMAU.